Astrazeneca Pharma India Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8227 as of 04 May 09:16 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 9024 crore as compare to the Sep '25 revenue of ₹ 9158 crore. This represent the decline of -1.46% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Dr Reddys Laboratories Ltd for the Dec '25 is ₹ 2158 crore as compare to the Sep '25 ebitda of ₹ 2340 crore. This represent the decline of -7.76% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 1189 crore over 7 quarters. This represents a CAGR of -8.60% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Dr Reddys Laboratories Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Dr Reddys Laboratories Ltd is 110,420 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Dr Reddys Laboratories Ltd?

As of May 4, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1322.95.

How do dividend payouts of Astrazeneca Pharma India Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.